Piramal Pharma Ltd.

NSE: PPLPHARMA · Healthcare

₹206.59

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bullish 62% confidence

Q1 FY27 operational inflection (17% revenue, 72% EBITDA growth, 400 bps margin expansion) and intact bullish technicals outweigh low…

Strongest bull point

Q1 FY27 confirmed 17% revenue growth and 72% EBITDA growth with 400 bps margin expansion across all three segments, signaling genuine operational recovery post-FY26 impairment overhang.

Strongest bear point

₹176 crore FY26 impairment signals asset quality deterioration; 12-month absolute return of only +3.53% (vs +12.17% relative to weak NIFTY) and subdued volume (0.78x average) suggest momentum-driven repricing lacking institutional conviction.

Technical Forecast · next 10 trading days

Expected

₹182.43 -11.7%

Range

₹181.44 – ₹182.76

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on PPLPHARMA, misses included

Bullish 28 Sep 2026 → now Scores 28 Oct 2026

₹206.59 → ₹206.59 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare